Abstract
The authors wholeheartedly agree that investigation of the use of laparoscopic nephrectomy in the management of Wilms’ tumor must be undertaken with caution and by those surgeons skilled in advanced laparoscopic surgery, including retroperitoneal lymphadenectomy. Certainly improved cosmesis and possible quicker recovery do not warrant the increased risk of tumor recurrence or the added morbidity of adjuvant radiation therapy should further trials show inferior oncologic outcomes with laparoscopic nephrectomy. However, we respectfully differ in opinion with Dr. Ross concerning the question of a trial of laparoscopic nephrectomy being an ‘‘ethical dilemma’’ due to its unproven nature. All current medical therapy once began as unproven treatment. It is the very idea of optimizing outcome while minimizing morbidity that leads our Hematology-Oncology colleagues to conduct well-designed and controlled trials utilizing alternative treatment regimens for a variety of malignancies. These very trials have resulted in the current
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
